PTC reports prelim 2023 revenue $946M (+35% YoY); guides 2024 rev $600-850M

PTC THERAPEUTICS, INC.

2023-FY EPS reported -$8.37 revenue$937,822,000

Unaudited 2023 total revenue $946M (+35% YoY); net product revenue $661M (+23% YoY).
DMD franchise: Translarna $355M, Emflaza $255M; Evrysdi royalty/collab revenue $278M.
2024 revenue guidance $600-850M (decline); GAAP R&D+SG&A $740-835M; non-GAAP $660-755M.
Sepiapterin MAA in EU Q1, NDA in US by Q3; PTC518 HD interim data Q2.
CHMP opinion on Translarna re-examination late Jan 2024; $1B Royalty Pharma deal closed.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PTC THERAPEUTICS, INC. reported full year 2024 results: revenue $600 million to $850 million. Guidance initiated.

Period: full year 2024
Revenue: $600 million to $850 million
Guidance: initiated
Result: guidance update

Exact text from the filing

PTC anticipates total revenues for the full year 2024 to be between $600 million and $850 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PTC THERAPEUTICS, INC. reported full year 2023 results: revenue $946 million.

Period: full year 2023
Revenue: $946 million
Result: preliminary results

Exact text from the filing

Total unaudited net revenue for full year 2023 was approximately $946 million.

View on SEC.gov

Browse all earnings releases →

PTC THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001070081-24-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.